Skip to content Skip to footer
Subscribe Now
NEWS

George Medicines Partners with Ahngook Pharmaceutical to Commercialize GMRx2 in Korea

Shots: George Medicines has entered into an exclusive licensing & supply agreement with Ahngook Pharmaceutical, granting rights to seek regulatory approval & commercialize GMRx2 in Korea for the treatment of Hypertension As per the deal, George Medicines will receive an upfront licensing fee, potential regulatory & commercial milestone payments, as well as stepped royalties on…
March 12, 2026

Read more

NEWS

Rapport Therapeutics Partners with Tenacia Biotechnology to Advance RAP-219 in Greater China

Shots: Rapport Therapeutics has granted Tenacia exclusive rights to develop & commercialize RAP-219 in Greater China across indications, incl. focal onset seizures (FOS) & bipolar mania, with Rapport retaining rights in other territories As per the deal, Rapport will receive $20M upfront & ~$308M in development & commercialization milestones & other payments, plus mid-single digits…
March 10, 2026

Read more

NEWS

GAIA and Daiichi Sankyo Europe Partner to Launch Lipodia for Hypercholesterolemia in Europe

Shots: GAIA has entered into an exclusive strategic partnership with Daiichi Sankyo Europe to commercialize Lipodia, a digital therapeutic designed to support adults living with hypercholesterolemia, upon regulatory approval As per the deal, Daiichi Sankyo Europe will obtain exclusive rights to lipodia, initially covering Germany, with provisions to expand the partnership across major EU markets…
March 6, 2026

Read more

NEWS

Tenaya Therapeutics and Alnylam Pharmaceuticals Partner to Discover Novel Genetic Targets for CV Therapies in ~$1.13B Deal

Shots: Tenaya has entered into a research collaboration with Alnylam to identify novel human genetic targets that could enable the development of disease-modifying therapies for cardiovascular (CV) diseases Under the collaboration, Tenaya will validate up to 15 gene targets, while Alnylam will lead all the development & commercialization of therapies arising from these validated targets…
March 6, 2026

Read more

NEWS

Teva Lands $400M Blackstone Life Sciences Deal to Support Duvakitug Development

Shots: Teva & Blackstone Life Sciences have entered a four-year strategic funding agreement to support the continued clinical development of duvakitug As per the deal, Blackstone will provide $400M to Teva over four years to fund duvakitug development, while Blackstone will receive potential milestone payment subject to FDA approval, & additional commercial milestones, as well…
March 5, 2026

Read more

NEWS

Sino Biopharmaceutical and Sanofi Partner to Advance Rovadicitinib in a ~$1.53B Deal

Shots: Sino Biopharm via its subsidiary Chia Tai Tianqing has entered into an exclusive license agreement with a fully owned subsidiary of Sanofi for rovadicitinib As per the deal, Sanofi will obtain exclusive global license to develop, manufacture & commercialize rovadicitinib in exchange for $135M upfront & ~$1.395B in development, regulatory & sales milestones, as…
March 5, 2026

Read more

NEWS

Antengene and UCB Strike ~$1.18B Deal to Advance ATG-201 for B-Cell–Related Autoimmune Diseases

Shots: Antengene has granted UCB a global exclusive license to develop, manufacture, & commercialize ATG-201 for B-cell–related autoimmune diseases, plus access to Antengene’s associated manufacturing tech supporting the therapy As per the deal, Antengene will receive $80M in upfront & near-term milestones & ~$1.1B in development & commercial milestones, as well as net sales-based tiered…
March 5, 2026

Read more

Load more